Sabby Volatility Fund Discloses 661,056 Shares in Avenue Therapeutics
Ticker: ATXI · Form: SC 13G/A · Filed: Jan 2, 2024 · CIK: 1644963
| Field | Detail |
|---|---|
| Company | Avenue Therapeutics, INC. (ATXI) |
| Form Type | SC 13G/A |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**Sabby Volatility Fund holds 661,056 shares of Avenue Therapeutics, signaling continued institutional interest.**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd. filed an amended SC 13G/A on January 2, 2024, disclosing a shared beneficial ownership of 661,056 shares of Avenue Therapeutics, Inc. common stock as of December 31, 2023. This filing indicates a significant institutional stake in Avenue Therapeutics, a pharmaceutical company, and is important for investors as it shows a major fund's continued interest and position in the company, potentially signaling confidence or a strategic play.
Why It Matters
This filing reveals a major institutional investor's stake, which can influence stock price and investor sentiment for Avenue Therapeutics, Inc.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, indicating a stable or slightly adjusted institutional position rather than a new, volatile event.
Analyst Insight
Investors should monitor future filings from Sabby Volatility Warrant Master Fund, Ltd. for any changes in their position, as a significant increase or decrease could signal a shift in institutional confidence in Avenue Therapeutics, Inc.
Key Numbers
- 661,056 — Shares Beneficially Owned (Represents the total number of shares of Avenue Therapeutics, Inc. common stock held by Sabby Volatility Warrant Master Fund, Ltd.)
Key Players & Entities
- Sabby Volatility Warrant Master Fund, Ltd. (company) — reporting person and beneficial owner
- Avenue Therapeutics, Inc. (company) — issuer of the common stock
- 661,056 (dollar_amount) — number of shares beneficially owned
- December 31, 2023 (date) — date of event requiring the filing
- Cayman Islands (company) — place of organization for Sabby Volatility Warrant Master Fund, Ltd.
Forward-Looking Statements
- Sabby Volatility Warrant Master Fund, Ltd. will maintain a significant stake in Avenue Therapeutics, Inc. for the foreseeable future. (Sabby Volatility Warrant Master Fund, Ltd.) — medium confidence, target: Q2 2024
FAQ
Who is the reporting person in this SC 13G/A filing?
The reporting person in this SC 13G/A filing is Sabby Volatility Warrant Master Fund, Ltd., as stated in Item 1 of the filing.
What is the name of the issuer whose securities are being reported?
The name of the issuer is Avenue Therapeutics, Inc., as identified in the 'Name of Issuer' section of the filing.
How many shares of Avenue Therapeutics, Inc. common stock are beneficially owned by the reporting person?
The reporting person, Sabby Volatility Warrant Master Fund, Ltd., beneficially owns 661,056 shares of Avenue Therapeutics, Inc. common stock, as detailed in Row 9 of the cover page.
What was the date of the event which required this filing?
The date of the event which required this filing was December 31, 2023, as specified in the 'Date of Event Which Requires Filing of this Statement' section.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 2, 2024 regarding AVENUE THERAPEUTICS, INC. (ATXI).